MENLO PARK, Calif. (AP) _ Intersect ENT Inc. (XENT) on Wednesday reported a loss of $4.2 million in its second quarter.

The Menlo Park, California-based company said it had a loss of 14 cents per share.

The results exceeded Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for a loss of 17 cents per share.

The maker of absorbable nasal implants posted revenue of $26.3 million in the period, which missed Street forecasts. Six analysts surveyed by Zacks expected $28.1 million.

For the current quarter ending in October, Intersect ENT said it expects revenue in the range of $23.8 million to $24.3 million.

The company expects full-year revenue in the range of $106 million to $109 million.

Intersect ENT shares have dropped slightly since the beginning of the year. The stock has risen 18 percent in the last 12 months.


This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on XENT at

blog comments powered by Disqus